VBL To Test Gene Therapy In Phase III After FDA Lifts Hold
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Israeli biotech will commence its Phase III recurrent glioblastoma trial in mid-2015, believes combination therapy with its VB-111 and Avastin can improve overall survival. As it starts its first Phase III trial, VBL also halted work on its lead anti-inflammatory product.